Agoracom Blog Home

Archive for the ‘AGORACOM Sector Spotlight’ Category

« Older Entries

Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

Posted by Brittany McNabb at 12:09 PM on Tuesday, November 11th, 2025

Quantum BioPharma Ltd. (NASDAQ/CSE: QNTM; FRA: 0K91) today reported a strong third quarter, marking continued progress across both financial and scientific fronts. The biopharmaceutical company, focused on developing innovative treatments for neurodegenerative, metabolic, and alcohol-related conditions, demonstrated clear operational discipline while advancing its clinical and consumer health initiatives.

Financial Turnaround Anchored by Balance-Sheet Strength

Quantum BioPharma delivered significant quarter-over-quarter improvement, underscoring the company’s strengthened financial foundation. Shareholder equity increased 275%, while the debt-to-equity ratio improved by 86%, driven largely by the full elimination of liabilities related to previously issued convertible debentures.

Total liabilities declined from US $13.2 million to US $6.6 million, and general and administrative expenses were reduced by 8%. Liquidity improved substantially, with the current ratio rising to 1.41x from 0.78x in the prior quarter. Collectively, these results reaffirm the company’s “no going concern” position and extend its cash runway beyond March 2027.

Quantum also realized US $572,000 in gains from its digital-asset portfolio, primarily Bitcoin, as part of a diversified treasury strategy. As of September 30, 2025, the company held US $5.2 million in digital assets, up from US $0.8 million at year-end 2024, further enhancing its financial flexibility.

Lucid-MS: Advancing a New Approach to Multiple Sclerosis

At the core of Quantum’s R&D pipeline is Lucid-21-302 (Lucid-MS), a patented, first-in-class oral drug candidate designed to target the underlying biology of demyelination — the process that drives nerve-fiber damage in Multiple Sclerosis (MS).

The company recently completed 3- and 6-month oral toxicity studies that showed no toxicity or adverse side effects, a key milestone supporting advancement toward a Phase 2 human efficacy trial. Lucid-MS’s oral formulation offers a convenient alternative to existing MS therapies that require injections or infusions.

Quantum has also partnered with Massachusetts General Hospital (MGH) researchers in a joint PET imaging study to validate a new approach for monitoring myelin integrity in MS patients. In parallel, the company has engaged a global pharmaceutical development organization to prepare an Investigational New Drug (IND) submission to the U.S. FDA.

“Lucid-MS represents a new direction in MS treatment — one focused on protecting myelin and addressing the biological drivers of neurodegeneration,” said Zeeshan Saeed, President and Chief Executive Officer.

Expanding Consumer Health and Diversified Assets

Beyond its pharmaceutical programs, Quantum continues to expand its portfolio of commercially active consumer health assets.

Its licensed product unbuzzd™, designed to accelerate alcohol metabolism and ease hangover symptoms, is marketed in the United States by Unbuzzd Wellness Inc. The licensee launched powder stick packs in late 2024 and has since initiated a Reg D  financing of up to US $5 million in preparation for a potential initial public offering — without any equity dilution to Quantum.

In Canada, Health Canada has granted a Product License for Qlarity™, a natural-health formulation that supports energy, metabolism, and cognitive performance. Qlarity™ complements Quantum’s broader focus on neurological health and wellness.

Sustained Progress and Long-Term Vision

The third quarter also saw continued progress in Quantum’s efforts to address alleged market manipulation of its stock. Management confirmed that all hedge-fund-held warrants have now expired, and that a special dividend of Contingent Value Rights (CVRs) was distributed to Class B shareholders in October 2025.

Looking ahead, Quantum BioPharma plans to maintain disciplined financial management while advancing its clinical and consumer-health milestones. The company’s balance-sheet strength, diversified portfolio, and advancing MS program collectively establish a foundation for sustained growth in 2026 and beyond.

With a Phase 2 trial for Lucid-MS approaching and a global consumer-health pipeline expanding, Quantum BioPharma remains positioned at the intersection of biotechnology innovation, financial resilience, and long-term therapeutic impact.

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, AGORACOM Traffic, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Cuts Liabilities in Half, Boosts Equity 275%, and Strengthens Path to Phase 2 MS Trial

From 363K oz Gold to 413M lbs Nickel — Renforth Resources Powers Ahead with Dual-Track Growth Strategy

Posted by Brittany McNabb at 11:56 AM on Tuesday, November 11th, 2025

From 363K oz Gold to 413M lbs Nickel — Renforth Resources Powers Ahead with Dual-Track Growth Strategy

Renforth Resources Inc. (CSE: RFR; OTCQB: RFHRF; FSE: 9RR) continues to advance its dual focus on gold and critical minerals in Quebec’s Abitibi mining district — one of the world’s most prolific and infrastructure-rich jurisdictions. With 100% ownership of both the Parbec Gold Deposit and the Victoria Nickel-Polymetallic System, Renforth is strategically positioned at the intersection of two enduring global trends: gold’s role as a store of value and the accelerating demand for energy-transition metals such as nickel, copper, and cobalt.

Parbec Gold Deposit: Surface Work Strengthens Geological Model

Renforth recently completed a successful stripping program at the Parbec Gold Deposit, located adjacent to Agnico Eagle’s Canadian Malartic Mine. Covering approximately 2,200 square metres within the open-pit design area, the campaign marked the company’s first large-scale surface exposure program at Parbec.

Field crews identified several previously unrecognized faults and structural features intersecting the Cadillac Break — a prolific, gold-bearing corridor responsible for millions of ounces of historical production across the Abitibi. Visual observations and sampling confirmed lithologies previously observed only in drill core. These discoveries reinforce Renforth’s interpretation of Parbec as a structurally complex, open-ended system with meaningful near-surface potential.

While cold weather limited full channel sampling, grab samples were collected and dispatched for assay. Additional trenching, mapping, and sampling are planned for spring. This fieldwork supports Parbec’s updated 2025 mineral resource estimate of approximately 363,000 ounces of gold, representing a 29% increase from prior estimates, with 87% of ounces contained within an optimized open-pit shell.

Victoria Nickel-Polymetallic System: NI 43-101 Technical Report Filed

Renforth also filed its NI 43-101 Technical Report for the Malartic Metals Package, including the maiden Inferred Mineral Resource Estimate for the Victoria Nickel Sulphide Polymetallic Deposit. The resource outlines 125 million tonnes grading 0.15% nickel equivalent (NiEq) — approximately 413 million pounds of contained NiEq within a 2.5-kilometre section of a 20-kilometre-long mineralized trend.

The Technical Report confirms that Victoria remains open along strike and at depth, with drilling extending to 320 metres below surface. The open-pit model features a strip ratio of less than 1:1, indicating potential for efficient extraction. Hosted within interlayered ultramafic and black-shale units, the deposit also contains cobalt, copper, zinc, and precious-metal credits, providing exposure to multiple critical-mineral markets.

The report further highlights additional regional targets within the Malartic Metals Package — including the Beaupré copper discovery (stripped and sampled over 180 metres of strike), the Lac Surimau gold zone, and lithium anomalies near Victoria. Together, these prospects underscore the district-scale, multi-metal potential of the property, supported by ready access to roads, hydro power, and nearby processing infrastructure.

Strengthened Technical Foundation and Financing Momentum

Renforth’s field progress has been supported by the first tranche of its ongoing financing to advance exploration and technical programs across both Parbec and Victoria. The company’s disciplined strategy — combining targeted fieldwork with continued resource definition — is solidifying its technical foundation and operational readiness.

At Parbec, the emphasis on surface exposure and geologic refinement is designed to convert modeled mineralization into demonstrable, near-surface ounces. At Victoria, the completion of the NI 43-101 report establishes a baseline for future economic and development studies — a critical step in defining the project’s long-term potential.

Outlook: Balanced Growth for a Changing Market

Renforth’s dual-track strategy reflects balance and foresight — advancing a proven gold asset in a world-class mining district while building exposure to the metals essential for the energy transition. Both projects benefit from road access, grid power, and proximity to established infrastructure, enabling efficient, low-impact exploration.

As work resumes in 2026, Renforth remains focused on two complementary objectives: unlocking near-surface gold value at Parbec and expanding its nickel-polymetallic footprint at Victoria. This balanced approach continues to strengthen the company’s position as a diversified Quebec-based explorer poised to benefit from both stability in precious metals and growth in the critical-minerals economy.

YOUR NEXT STEPS

Visit $RFR HUB On AGORACOM:https://agoracom.com/ir/RenforthResources

Visit $RFR 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/RenforthResources/profile

Visit $RFR Official Verified Discussion Forum On AGORACOM:https://agoracom.com/ir/RenforthResources/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

 

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

 

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

 

If you have any questions, please direct them to [email protected]

For our full website disclaimer, please visithttps://agoracom.com/terms-and-conditions

 

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Renforth Resources | Comments Off on From 363K oz Gold to 413M lbs Nickel — Renforth Resources Powers Ahead with Dual-Track Growth Strategy

Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

Posted by Brittany McNabb at 3:58 PM on Friday, October 31st, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) has formally launched a public whistleblower reward program, offering up to USD $7 million to any individual or entity who can provide definitive, verifiable evidence that they were asked, hired, or induced to manipulate the Company’s stock.

This initiative is directly tied to Quantum’s ongoing landmark litigation, which alleges multi-year market manipulation and seeks damages exceeding USD $700 million.

✅ Anonymous submissions are accepted
✅ Confidentiality will be protected to the fullest extent permitted by law
✅ This program does NOT replace SEC or Canadian regulatory whistleblower programs — individuals may qualify for BOTH

How to Submit Information (Direct & Confidential)

[email protected]

Ineligible to Apply

  • Current officers, directors, or employees of Quantum BioPharma
  • Government officials/regulators acting in official capacity
  • Anyone who obtained information illegally or in violation of duty
  • Anyone submitting false or fabricated information

Important Legal Clarification

Rewards are not guaranteed and will only be paid if the submitted information materially contributes to a final, non-appealable legal judgment or binding settlement in the Company’s favor.

Quantum will not use any information provided until compensation terms are agreed to in writing with the whistleblower.

For full program details and FAQ, visit: QuantumBioPharma.com
This statement is issued in the interest of market integrity and shareholder protection.

Disclaimer

This Reward Program is discretionary and subject to change or withdrawal at any time without notice. Reward eligibility does not depend on whether a whistleblower testifies, awards are based on the contribution and reliability of the information. Quantum Biopharma will not direct, script, or influence any witness testimony. Rewards are not payments for testimony. Payment of any reward is contingent upon legal review, Board approval, and the successful outcome of a final, non‑appealable judgment or binding settlement of ongoing or future litigation pursued by the Quantum BioPharma at trial to which the reported information materially contributes. Nothing in this FAQ creates a contractual right to payment. This program does not replace, restrict or limit rights under the U.S. Securities and Exchange Commission (SEC) Whistleblower Program or whistleblower programs operated by Canadian regulatory authorities, and individuals remain free to report directly to the SEC and Canadian regulatory authorities.

 

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Launches USD $7 Million Reward Program for Proof of Market Manipulation

The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Posted by Brittany McNabb at 3:39 PM on Wednesday, October 29th, 2025

Quantum BioPharma (NASDAQ/CSE: QNTM) is advancing a novel therapeutic approach to Multiple Sclerosis (MS) — one centered not on suppressing the immune system, but on targeting the underlying biology of demyelination, the core driver of neurodegeneration in MS. To understand why this approach matters, it’s critical to understand the role of the myelin sheath.

What Is the Myelin Sheath and Why Does It Matter?

The myelin sheath is a fatty, insulating layer that wraps around nerve cell axons — acting like the high-speed wiring system of the nervous system. It is produced by specialized glial cells: oligodendrocytes in the central nervous system (CNS) and Schwann cells in the peripheral nervous system.

Myelin’s value comes from four critical functions:

  • Insulation: Prevents electrical “leaks” in signal transmission
  • Speed: Enables saltatory conduction — signals “jump” node to node (up to 100× faster)
  • Efficiency: Reduces the energy neurons need to fire signals
  • System control: Supports cognition, movement, perception, and coordination

Without myelin, the electrical messages between brain and body slow, weaken, or misfire — leading to the symptoms widely associated with neurological disorders like MS.

What Happens in Multiple Sclerosis

In MS, the myelin sheath is progressively damaged — historically thought to be caused only by immune system attack. However, leading researchers now point to a second process at play: a degenerative component that occurs independently of immune activity.

Both pathways lead to demyelination — the loss or disruption of the myelin sheath — resulting in impaired communication between neurons.

This degradation is what produces the hallmark symptoms of MS:

  • Loss of motor coordination
  • Impaired sensory perception
  • Declining cognitive function
  • Fatigue and loss of balance

Quantum BioPharma’s Approach: Precision Neuroprotection

Unlike conventional immunosuppressive MS treatments, Lucid-MS – Quantum’s patented lead drug candidate — is not immunomodulatory.

Instead, it is designed to address demyelination at the biological level, advancing a neuroprotective strategy that could complement, rather than compete with, existing immune-focused treatments.

Lucid-MS has completed successful Phase 1 human safety trials, with no serious adverse events reported. Multiple animal studies have demonstrated significant activity relevant to demyelination biology, providing additional confidence as Quantum advances toward a Phase 2 clinical trial in people with MS.

A Thoughtful, Science-Driven Evolution in MS Treatment Strategy

The global MS treatment market is heavily concentrated on slowing immune system attack. Quantum BioPharma is moving deeper — focusing on the root mechanisms of nerve damage itself.

Its approach signals an evolution in neuroscience:

  • From suppression → to protection 
  • From reaction → to resilience 
  • From slowing disease → to targeting its biological engine 

Looking Ahead

Quantum BioPharma is positioning Lucid-MS within the growing global focus on regenerative and neuroprotective medicine. As regulatory preparation accelerates, the company continues to emphasize precision science, data integrity, and clinical depth — not speculation.

For official clinical progress updates, visit: www.QuantumBioPharma.com

Visit $QNTM HUB On AGORACOM :https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

 

DISCLAIMER AND DISCLOSURE

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews/video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

 

Tags: , , , , , ,
Posted in AGORACOM Sector Spotlight, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on The Critical Role of the Myelin Sheath – And How Quantum BioPharma Is Advancing the Next Frontier in MS Neuroprotection

Lancaster Resources Launches Field Work at Lake Cargelligo Gold Project — Described by CEO as a ‘Potential Company-Maker’

Posted by Brittany McNabb at 5:25 PM on Friday, August 15th, 2025

Junior explorer advances a multi-asset portfolio while launching field work for its maiden NI 43-101 at Lake Cargelligo.

Vancouver — Lancaster Resources Inc. (CSE: LCR | OTC: LANRF | FRA: 6UF0) has begun desk and field work at its 100%-owned Lake Cargelligo Gold Project in New South Wales, Australia—an early but important step toward completing the company’s first National Instrument 43-101 technical report on the asset. The program marks tangible progress following a year of portfolio building across gold, uranium and polymetallic targets in Canada and Australia.

The initiative matters for two reasons. First, Lake Cargelligo sits in the prolific Lachlan Fold Belt and covers 28,768 hectares with multiple historical gold and silver occurrences. Second, a maiden NI 43-101 establishes a standardized technical baseline for future work, helping the company prioritize targets and sequence capital.

Background and Context

Lancaster is assembling district-scale exploration positions in mining-friendly jurisdictions. Its portfolio includes the Lake Cargelligo Gold Project in Australia; the Piney Lake gold property in Saskatchewan; the Catley Lake and Centennial East uranium projects in Saskatchewan’s Athabasca Basin; and Quebec’s Lac Iris polymetallic project in the James Bay region, where the company also holds an option on the Trans-Taiga property. In Australia, Lancaster operates through a wholly owned subsidiary created to advance exploration and development.

At Lake Cargelligo, historical work reported surface rock-chip results up to 204 grams per tonne (g/t) gold and 273 g/t silver, and channel sampling intercepts up to 16 meters at 5.83 g/t gold and 7.20 g/t silver. These figures, disclosed by the company, are historical and have not yet been verified by a Qualified Person under NI 43-101, but they frame the initial areas of interest for the 2025 work program.

Key Highlights and Advantages

  • Field work underway: Reconnaissance geological mapping and rock-chip sampling have commenced to refine targets for a focused drill program. 
  • Maiden NI 43-101 in process: Lancaster anticipates completing the report by August 31, 2025, providing a structured technical foundation for the project. 
  • District scale: Lake Cargelligo covers 28,768 hectares in the Lachlan Fold Belt, a region known for significant gold endowment. 
  • Portfolio breadth: Active positions in gold (Australia and Saskatchewan), uranium (Athabasca Basin), and polymetallic targets (James Bay) offer multiple exploration pathways. 

What differentiates the current phase is movement from claim consolidation to on-the-ground work—paired with a clear reporting milestone and a stated plan to progress toward drill targeting.

Potential Impact and Significance

For the company, the field program at Lake Cargelligo is a practical inflection point. A completed NI 43-101 should help prioritize targets, guide future budgets and timelines, and provide a consistent technical reference for subsequent results. Portfolio breadth—across gold, uranium and polymetallics—also allows Lancaster to pursue opportunities that align with commodity cycles while concentrating near-term activity where access, permitting and historical data support a faster start.

Expert Opinions and Analysis

“Commencing field work at Lake Cargelligo represents a pivotal moment for Lancaster,” said Andrew Watson, P.Eng., President and CEO. “Our maiden NI 43-101 Technical Report for Lake Cargelligo will be the foundation for systematic exploration, guiding our strategy toward resource definition and value creation for our shareholders.” Watson is the company’s Qualified Person as defined under NI 43-101 and has reviewed and approved the scientific and technical information in the news release.

Separately, Lancaster confirmed it has engaged Ora IR Services Inc. to support investor relations, including customer service management and communications. The agreement includes the grant of 1.8 million stock options exercisable at $0.10 per share and monthly cash compensation between $10,000 and $20,000, with Ora’s principal, Geoff Skinner, acting as consultant.

Challenges and Considerations

As an early-stage explorer, Lancaster faces common risks: historical results require modern verification; timelines can be affected by permitting, access, and seasonal field conditions; and mineralization on adjacent or nearby properties is not necessarily indicative of mineralization on Lancaster’s ground. The company notes that historical results cited at Lake Cargelligo have not been verified by a Qualified Person. In Quebec, the Lac Iris claims remain “Being Processed” pending confirmation from SIGEOM and the provincial ministry.

Mitigation steps include sequencing work toward a formal NI 43-101, focusing initial efforts on mapping and sampling to de-risk drill targeting, and coordinating programs across projects (including planned hyperspectral analysis in James Bay) to improve efficiency.

Conclusion

Lancaster Resources is moving from portfolio assembly to execution. With field work underway at Lake Cargelligo and a clear target date for its maiden NI 43-101, the company is laying the technical groundwork needed to advance a district-scale gold asset—all while maintaining exposure to uranium and polymetallic opportunities in Canada. For a junior explorer, that combination of focus on a lead project and optionality across the broader portfolio may prove decisive as 2025 unfolds.

YOUR NEXT STEPS

Visit $LCR HUB On AGORACOM:http:// https://agoracom.com/ir/Lancasterresources

Visit $LCR 5 Minute Research Profile On AGORACOM:https://agoracom.com/ir/Lancasterresources/profile

Visit $LCR Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Lancasterresources/forums/discussion

 

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

 

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.

 

In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.  

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Lancaster Resources | Comments Off on Lancaster Resources Launches Field Work at Lake Cargelligo Gold Project — Described by CEO as a ‘Potential Company-Maker’

Zefiro Hits $57M Revenue + $20M in State Contracts Sealing Methane Leaks

Posted by Paul Nanuwa at 12:04 PM on Thursday, July 17th, 2025

Zefiro Methane Corp. (CBOE Canada: ZEFI | OTCQB: ZEFIF), a vertically integrated environmental services company, has surpassed USD $57 million in revenue across fiscal 2024 and year-to-date fiscal 2025. The company also recently secured approximately USD $20 million in contracts from the State of Ohio to permanently seal over 200 orphaned oil and gas wells — marking a significant step in its mission to address methane emissions across North America.

In a recent interview, Interim CEO Catherine Flax joined AGORACOM founder George Tsiolis to provide insight into the scope and significance of these contracts, as well as the company’s broader strategy for climate infrastructure and carbon monetization.

Leadership with Financial and ESG Credentials

Catherine Flax brings deep financial and regulatory experience to Zefiro, having held executive roles at JPMorgan and BNP Paribas. She emphasized Zefiro’s focus on combining environmental integrity with financial discipline:

“We’re not just solving an environmental problem — we’re creating a scalable model that generates recurring revenue while supporting real-world emissions reduction.”

Her leadership comes at a pivotal time, as the company moves from early traction to broader execution.

Ohio Contracts Signal Operational Momentum

The USD ~$20 million in contracts were awarded by the Ohio Department of Natural Resources. Under these agreements, Zefiro — through its wholly owned subsidiary Plants & Goodwin — is tasked with the safe and permanent sealing of more than 200 orphaned wells across the state.

Key contract highlights include:

  • Approx. USD $20 million in total value
  • 200+ wells slated for permanent abandonment
  • Significant reduction of fugitive methane emissions
  • Execution by in-house crews using proprietary equipment
  • Verified carbon credits tied to emissions abatement

Zefiro has also pre-sold carbon credits to major counterparties, including Mercuria and EDF Trading, providing forward visibility into cash flows.

Fully Integrated Methane Abatement Model

Zefiro’s value proposition lies in its end-to-end model — from detection through monetization:

  • Detection: Satellite and drone-based methane identification
  • Execution: In-house plugging by subsidiary Plants & Goodwin
  • Verification: Independent third-party validation
  • Monetization: Origination and pre-sale of carbon offset credits

This integrated structure allows Zefiro to control quality, manage costs, and improve gross margins across projects.

Scalable Growth with Tangible Results

Since inception, Zefiro has generated more than USD $57 million in revenue, including USD $32.8 million in FY2024 and USD $24.4 million YTD FY2025. The company’s current trajectory is shaped by awarded contracts, a defined regulatory opportunity, and a replicable operational model.

Zefiro continues to participate in bid processes across multiple jurisdictions in the United States, positioning itself as a long-term partner in orphaned well remediation and methane mitigation.

Targeting a Multi-Billion Dollar Market

According to various public and academic sources, North America’s orphaned well liability is estimated to exceed $400 billion in cumulative cleanup costs. Zefiro is building the operational and administrative infrastructure required to compete for a growing share of this market — with a focus on compliant execution, verified impact, and recurring revenue.

Conclusion: Positioned for Scale in Climate Infrastructure

Zefiro Methane Corp. is establishing itself as a practical solution provider in the climate infrastructure space. By aligning environmental outcomes with a disciplined business model, the company is delivering measurable impact — and building what could become a leading platform for methane abatement and carbon credit origination.

“Environmental responsibility and strong financial performance are not mutually exclusive,” said Flax. “We’re proving they can power each other.”

YOUR NEXT STEPS 

Visit $ZEFI HUB On AGORACOM: https://agoracom.com/ir/ZefiroMethaneCorp

Visit $ZEFI 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/ZefiroMethaneCorp/profile

Visit $ZEFI Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/ZefiroMethaneCorp/forums/discussion

Watch $ZEFI Videos On AGORACOM YouTube Channel: https://www.youtube.com/@AGORACOMIR

 

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

Tags: , , , , , , , , , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap 60, AGORACOM Small Cap Stocks For Investment, AGORACOM Small-Cap TV, AGORACOM Traffic, Zefiro Methane Corp | Comments Off on Zefiro Hits $57M Revenue + $20M in State Contracts Sealing Methane Leaks

Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Posted by Brittany McNabb at 9:55 AM on Friday, June 27th, 2025

Quantum BioPharma (NASDAQ: QNTM / CSE: QNTM) is now facing one of the most severe short pressure environments observed in North American markets this year. The borrow fee on QNTM shares has surged past 437% annually — roughly 1% per trading day — placing it among the highest-cost securities to short across any exchange. These fees signal that brokers are effectively out of lendable inventory and are pricing risk accordingly.

Float Scarcity Driving Volatility Risk

With fewer than 15,000 shares available for borrowing across major prime brokers, QNTM has entered what many refer to as a “locate vacuum.” The company’s public float is approximately 2.6 million shares, making it highly sensitive to buying pressure. In micro-float environments, even small bursts of covering or long-side accumulation can cause rapid price escalation due to a lack of natural sellers and tight liquidity conditions.

Dark Pool Activity Clouds Price Discovery

Adding to concerns is the high proportion of off-exchange short trading. In recent sessions, approximately 59% of QNTM’s daily volume has been routed through dark pools — private trading venues that do not display pre-trade quotes. While such routing is legal, this level of activity can obscure real demand and suppress visible momentum. In an environment where supply is tight and borrow costs are surging, dark pool dominance raises legitimate questions about whether price discovery is functioning as it should.

Echoes of Past Short-Driven Dislocations

The structural setup now surrounding QNTM bears striking similarities to prior market events that resulted in high-profile short squeezes. KaloBios (KBIO) gained over 10,000% in 2015 after its float was effectively locked and borrow availability vanished. GameStop (GME) surged 2,740% in early 2021 under conditions of high borrow fees, float constraints, and elevated short interest. Other comparables include Tilray (TLRY) and KOSS, where borrow fees exceeded 800% during moments of extreme float compression. QNTM’s current borrow rate already exceeds GME’s peak — despite having a much smaller float.

Company Fundamentals Remain Unchanged

While trading volatility has increased, Quantum BioPharma’s operational strategy and clinical programs remain firmly on track. The company recently completed Phase 1 trials for Lucid-MS, a novel treatment designed to repair myelin damage in multiple sclerosis patients. Developed in collaboration with scientists from a Harvard-affiliated teaching hospital, Lucid-MS offers a differentiated approach in a space long dominated by immune suppression therapies. Importantly, the company has made no promotional claims, has not issued new financings, and is not engaged in any stock-related marketing activity.

No Squeeze Assumptions — But Structural Tension Is Clear

A short squeeze is never guaranteed, even with elevated borrow fees and float scarcity. However, the structural tension in QNTM’s trading — characterized by near-zero share availability, high-cost borrow, and dark pool suppression — creates the potential for sudden dislocation if a trigger appears. Any combination of positive news, reduced volume, or insider accumulation could prompt a reflexive covering event in a market ill-equipped to absorb it.

Reaffirming the Need for Market Integrity

Quantum BioPharma has not commented on recent trading behavior but reaffirms its commitment to transparency, scientific advancement, and regulatory compliance. The company supports fair, orderly markets and believes that all participants — including regulators and exchanges — should remain vigilant when structural indicators point to breakdowns in natural price formation. As this situation evolves, investors, analysts, and oversight bodies are encouraged to monitor borrow fees, share availability, and trade routing closely.

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma Confronts Extreme Short Pressure Amid Market Imbalances as Borrow Fees Surge Beyond 437%

Draganfly Takes Flight: Momentum Builds Across Defense, Humanitarian, and Infrastructure Sectors

Posted by Brittany McNabb at 2:35 PM on Wednesday, May 28th, 2025

With a legacy of UAV innovation and a portfolio of real-world deployments, Draganfly Inc. (NASDAQ: DPRO | CSE: DPRO) is accelerating its reach across critical sectors—from battlefield logistics to disaster relief.

A Proven UAV Partner with Global Impact

Draganfly has spent over 25 years at the forefront of drone innovation. Today, that track record is translating into real-world impact across defense, public safety, infrastructure, and humanitarian missions.

In 2024, the company generated $6.56 million USD in revenue, and in Q1 2025, it posted a 16% year-over-year revenue increase, driven by rising demand for product sales—up 24.5%. From conflict zones in Ukraine to emergency responses in North America, Draganfly is redefining how unmanned aerial systems are used to save lives and enhance efficiency.

Strategic Expansion Meets Mission-Critical Demand

Draganfly’s momentum is anchored by high-profile partnerships and geographic expansion:

  •  Appointed by SafeLane Global as the preferred global drone partner for landmine mapping in over 60 conflict-affected countries, including active missions in Ukraine.
  •  Opened a U.S. defense facility in Tampa, Florida to support federal and public safety clients.
  •  Earned a key FAA waiver authorizing operations over people and moving vehicles—essential for urban drone missions.
  •  Partnered with Volatus Aerospace to deliver advanced aerial intelligence tools, including bathymetric LiDAR for high-precision surveying over water.

This is strategic execution in action—Draganfly is not just building drones; it’s building infrastructure for global resilience.

Drones Built for the Front Lines

Draganfly’s drone ecosystem is designed for critical, high-stakes missions:

  •  Commander 3XL: Trusted by the U.S. Department of Defense and Massachusetts Department of Transportation, this flagship platform supports tactical resupply, surveillance, and medical drone delivery.
  •  Heavy Lift Drone: Designed for large-payload delivery, from medical kits and comms gear to infrastructure materials—ideal for disaster relief and rugged logistics.
  •  APEX Platform: Supports thermal imaging, real-time overwatch, and situational awareness for emergency response and crisis coordination.

These systems are already deployed for wildfire response, search and rescue, and critical infrastructure inspection—backed by award-winning design and engineering.

Public Safety Expertise Strengthened at the Top

In May 2025, Draganfly appointed Peter Lambrinakos, O.O.M., CPP, to its Public Safety Advisory Board. A former Chief of Police at VIA Rail and senior official with the Montreal Police Service, Lambrinakos brings decades of leadership in national security, crisis response, and AI ethics in public safety.

His addition reinforces Draganfly’s commitment to delivering secure, non-foreign-made drone technology that meets the evolving demands of North American defense and public agencies.

Beyond the Battlefield: Humanitarian UAV Solutions

Draganfly’s work with SafeLane Global marks a major leap forward in UAV-based landmine detection—deploying drones to safely survey minefields and deliver mesh-based demining systems.

This initiative, combined with previous drone delivery missions of insulin in Ukraine, highlights Draganfly’s growing footprint in humanitarian tech—applying AI-powered aerial systems to the world’s most pressing emergencies.

Looking Ahead: Scaling Innovation with Purpose

With new U.S. operations, regulatory clearances, and critical defense and public safety partnerships, Draganfly is positioning itself as a trusted domestic drone supplier at a time when national security policies increasingly favor secure, North American-made UAV systems.

The company’s multi-use platforms—modular, AI-integrated, and built to perform—are redefining what’s possible across defense, infrastructure, and emergency response.

Draganfly isn’t just meeting demand—it’s shaping the future of aerial intelligence.

For more information, visitwww.draganfly.com.

YOUR NEXT STEPS

Visit $DPRO HUB On AGORACOM:http:// https://agoracom.com/ir/Draganfly 

Visit $DPRO 5 Minute Research Profile On AGORACOM:http:// https://agoracom.com/ir/Draganfly/profile

Visit $DPRO Official Verified Discussion Forum On AGORACOM:http:// https://agoracom.com/ir/Draganfly/forums/discussion

 Watch $DPRO Videos On AGORACOM YouTube Channel:

DISCLAIMER AND DISCLOSURE 

 This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

 AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

 This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit http://  https://agoracom.com/terms-and-conditions

Tags: , , , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, All Recent Posts, Draganfly Inc. | Comments Off on Draganfly Takes Flight: Momentum Builds Across Defense, Humanitarian, and Infrastructure Sectors

Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Posted by Brittany McNabb at 3:38 PM on Thursday, May 15th, 2025

The biopharmaceutical company’s legal action against major financial institutions underscores the persistent issue of spoofing in financial markets.

Introduction

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on developing treatments for neurodegenerative disorders, has filed a lawsuit seeking over $700 million in damages. The legal action alleges that CIBC World Markets and RBC Dominion Securities engaged in market manipulation practices, specifically spoofing, which artificially depressed Quantum’s stock price between January 2020 and August 2024. 

Understanding Spoofing and Its Impact

Spoofing is a deceptive trading practice where traders place large orders with the intent to cancel them before execution, creating a false impression of demand or supply. This manipulates market prices and can mislead other investors. The practice was outlawed under the Dodd-Frank Act in 2010 due to its potential to disrupt market integrity.

In Quantum’s case, the company alleges that such spoofing tactics led to a significant decline in its stock value, which was trading above $460 per share in January 2020. The purported manipulation not only affected the company’s market capitalization but also potentially harmed investors who relied on transparent market operations. 

Legal Proceedings and Representation

Quantum BioPharma has engaged the law firms Christian Attar and Freedman Normand Friedland LLP to represent its case on a contingency basis. This arrangement indicates the legal teams’ confidence in the merits of the case and ensures that Quantum can pursue the lawsuit without immediate financial burden. 

The lawsuit, filed in the U.S. District Court for the Southern District of New York, accuses the defendants of violating multiple sections of the Securities Exchange Act. Quantum has also invited shareholders who believe they were affected by the alleged spoofing to share their experiences, aiming to document the broader impact on investor confidence and market fairness. 

Advancements in Multiple Sclerosis Treatment

Amidst the legal battle, Quantum continues to advance its clinical programs. The company’s lead compound, Lucid-MS, is a first-in-class, non-immunomodulatory, neuroprotective treatment for multiple sclerosis (MS). Unlike traditional MS therapies that suppress the immune system, Lucid-MS aims to protect and restore the myelin sheath surrounding nerve fibers, addressing the root cause of the disease. 

In February 2025, Quantum announced the completion of its Phase 1 clinical trial for Lucid-MS, reporting that the treatment was well-tolerated with no serious adverse events. The company is now preparing to initiate Phase 2 trials, bringing it closer to offering a novel therapeutic option for MS patients.

Conclusion

Quantum BioPharma’s lawsuit against major financial institutions brings to light the ongoing challenges of ensuring market integrity in the face of sophisticated trading manipulations like spoofing. As the company seeks justice through legal channels, it remains committed to its mission of developing innovative treatments for debilitating diseases, exemplified by the progress of Lucid-MS.

Investors and industry observers will be closely monitoring the outcomes of both the legal proceedings and the clinical advancements, as they hold significant implications for market practices and medical breakthroughs alike.

Source: https://corporatefinanceinstitute.com/resources/career-map/sell-side/capital-markets/spoofing/

Visit $QNTM HUB On AGORACOM : https://agoracom.com/ir/Quantumbiopharma

Visit $QNTM 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/Quantumbiopharma/profile

Visit $QNTM Official Verified Discussion Forum On AGORACOM:

https://agoracom.com/ir/Quantumbiopharma/forums/discussion

DISCLAIMER AND DISCLOSURE 

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post. You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000. 

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

Tags: , , , , ,
Posted in AGORACOM Sector Spotlight, AGORACOM Small Cap Stocks For Investment, All Recent Posts, Quantum BioPharma Ltd. | Comments Off on Quantum BioPharma’s $700 Million Lawsuit Highlights Ongoing Concerns Over Market Manipulation

Plasma Power: How PyroGenesis Is Quietly Leading Heavy Industry’s Green Revolution

Posted by Brittany McNabb at 1:15 PM on Wednesday, April 30th, 2025


From high-efficiency torches to billion-dollar clients, this Canadian tech company is proving that clean heat can mean big business.

As global industries scramble to decarbonize and future-proof their operations, one Montreal-based company is emerging as a key enabler of the clean energy transition. PyroGenesis Inc. (TSX: PYR | OTCQX: PYRGF | FRA: 8PY1), a high-tech leader in all-electric plasma technologies, is gaining serious traction with some of the world’s largest players in aluminum, defense, aerospace, and steelmaking.

After a breakout 2024, the company is now sitting on a $54.4 million backlog of signed and awarded contracts — 87% denominated in U.S. dollars — and showing no signs of slowing down.

Turning Heat Into Revenue: Record Year, Profitable Quarter

PyroGenesis reported $15.7 million in revenue for FY2024, a 27% increase over the previous year. Q4 alone saw a 40% revenue boost year-over-year, clocking in at $4.22 million with a net income of $145,320 — a dramatic turnaround from the $9.8 million loss reported in Q4 2023.

This marked the seventh straight quarter of revenue growth, a sign of both strong execution and growing demand for the company’s ultra-high-temperature solutions. Gross margins improved to 41.3% in Q4, while SG&A expenses were slashed by $20 million year-over-year, reflecting strong cost discipline.

World-Class Clients, World-Changing Tech

PyroGenesis isn’t just innovating — it’s executing at scale with some of the world’s biggest industrial names:

  • Norsk Hydro, one of the largest aluminum producers globally, awarded PyroGenesis a ~$2.4 million contract to supply plasma torches for fossil fuel replacement at its flagship plant in Norway.
  • Boeing has entered into the final stages of certification to approve PyroGenesis’ NexGen™ titanium metal powder for aerospace applications.
  • A $27 million contract from a U.S. defense and aerospace contractor to build a 20-megawatt plasma torch — believed to be among the most powerful ever produced.
  • The U.S. Department of Defense tapped PyroGenesis to destroy toxic PFAS chemicals with its advanced plasma technology.

This kind of customer validation doesn’t happen by chance. It’s the result of more than a decade of R&D, patents, and performance.

Three Verticals, One Mission: Clean Industry

PyroGenesis’ strategy is built around three core business verticals — all aligned with global industrial needs:

  1. Energy Transition & Emission Reduction
     Replacing fossil fuel burners with electric plasma torches in steel, aluminum, and cement production.
  2. Waste Remediation
     Destroying toxic “forever chemicals” and hazardous waste with zero-emissions plasma tech.
  3. Commodity Security & Optimization
     Recovering critical minerals, creating high-purity powders, and transforming waste into valuable materials like renewable natural gas and fumed silica.

This diversified approach positions PyroGenesis not just as a clean tech company — but as an essential solutions provider for modern industry.

Operational Momentum and Market Tailwinds

2025 has opened with strong tailwinds. The company:

  • Secured new contracts with multi-billion-dollar clients in aluminum and waste-to-energy sectors.
  • Launched joint studies with GE Vernova, targeting furnace electrification for iron ore pelletization and aluminum smelting.
  • Advanced live-furnace testing for aluminum and steel plasma heating with multiple global manufacturers.

With governments and industries accelerating toward decarbonization targets, demand for factory-ready, emission-reducing technology is surging — and PyroGenesis is delivering.

The Bottom Line: Execution Meets Opportunity

PyroGenesis is no longer just a tech innovator — it’s a proven commercial operator with real clients, real contracts, and real momentum. Its plasma technologies are solving multi-billion-dollar problems across energy, defense, aerospace, and heavy manufacturing.

As industries demand cleaner, faster, and smarter ways to produce materials, PyroGenesis is answering with a rare combination: breakthrough innovation and operational scale.

This is one small-cap that’s powering some very big shifts.


YOUR NEXT STEPS 

Visit $PYR HUB On AGORACOM:http:// https://agoracom.com/ir/PyroGenesisCanada

Visit $PYR 5 Minute Research Profile On AGORACOM: https://agoracom.com/ir/PyroGenesisCanada/profile

Visit $PYR Official Verified Discussion Forum On AGORACOM: https://agoracom.com/ir/PyroGenesisCanada/forums/discussion

Watch $PYR Videos On AGORACOM YouTube Channel:

https://studio.youtube.com/video/PKBOqIcMQlg/edit

DISCLAIMER AND DISCLOSURE  

This record is published on behalf of the featured company or companies mentioned (Collectively “Clients”), which are paid clients of Agora Internet Relations Corp or AGORACOM Investor Relations Corp. (Collectively “AGORACOM”)

AGORACOM.com is a platform. AGORACOM is an online marketing agency that is compensated by public companies to provide online marketing, branding and awareness through Advertising in the form of content on AGORACOM.com, its related websites (smallcapepicenter.com; smallcappodcast.com; smallcapagora.com) and all of their social media sites (Collectively “AGORACOM Network”) .  As such please assume any of the companies mentioned above have paid for the creation, publication and dissemination of this article / post.

You understand that AGORACOM receives either monetary or securities compensation for our services, including creating, publishing and distributing content on behalf of Clients, which includes but is not limited to articles, press releases, videos, interview transcripts, industry bulletins, reports, GIFs, JPEGs, (Collectively “Records”) and other records by or on behalf of clients. Although AGORACOM compensation is not tied to the sale or appreciation of any securities, we stand to benefit from any volume or stock appreciation of our Clients.  In exchange for publishing services rendered by AGORACOM on behalf of Clients, AGORACOM receives annual cash and/or securities compensation of typically up to $125,000.

Facts relied upon by AGORACOM are generally provided by clients or gathered by AGORACOM from other public sources including press releases, SEDAR and/or EDGAR filings, website, powerpoint presentations.  These facts may be in error and if so, Records created by AGORACOM may be materially different. In our video interviews or video content, opinions are those of our guests or interviewees and do not necessarily reflect the opinion of AGORACOM.

From time to time, reference may be made in our marketing materials to prior Records we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

NO INVESTMENT ADVICE

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell products or securities.

You understand and agree that no content in this record or published by AGORACOM constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person and that no such content is tailored to any specific person’s needs. We will never advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

Neither the writer of this record nor AGORACOM is an investment advisor.  Both are neither licensed to provide nor are making any buy or sell recommendations. For more information about this or any other company, please review their public documents to conduct your own due diligence.

If you have any questions, please direct them to [email protected] 

For our full website disclaimer, please visit http://  https://agoracom.com/terms-and-conditions

Tags: , , , ,
Posted in AGORACOM Client Feature, AGORACOM Sector Spotlight, All Recent Posts, PyroGenesis Canada Inc. | Comments Off on Plasma Power: How PyroGenesis Is Quietly Leading Heavy Industry’s Green Revolution

« Older Entries